Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pliant Therapeutics (PLRX) Net Cash Flow (2019 - 2026)

Pliant Therapeutics has reported Net Cash Flow over the past 8 years, most recently at -$23.3 million for Q1 2026.

  • Quarterly Net Cash Flow fell 212.08% to -$23.3 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$69.7 million through Mar 2026, down 211.91% year-over-year, with the annual reading at -$25.7 million for FY2025, 423.65% down from the prior year.
  • Net Cash Flow was -$23.3 million for Q1 2026 at Pliant Therapeutics, up from -$48.3 million in the prior quarter.
  • Over five years, Net Cash Flow peaked at $68.8 million in Q1 2023 and troughed at -$48.3 million in Q4 2025.
  • The 5-year median for Net Cash Flow is -$5.1 million (2025), against an average of -$1.6 million.
  • Year-over-year, Net Cash Flow plummeted 30249.21% in 2022 and then skyrocketed 997.66% in 2025.
  • A 5-year view of Net Cash Flow shows it stood at -$10.9 million in 2022, then skyrocketed by 164.37% to $7.0 million in 2023, then crashed by 219.75% to -$8.4 million in 2024, then tumbled by 472.94% to -$48.3 million in 2025, then soared by 51.84% to -$23.3 million in 2026.
  • Per Business Quant, the three most recent readings for PLRX's Net Cash Flow are -$23.3 million (Q1 2026), -$48.3 million (Q4 2025), and $6.9 million (Q3 2025).